Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

Blood

Volumn 91, Issue 2, 1998, Pages 458-465

  Parker, Bernard W ^a   Kaur, Gurmeet ^a   Nieves Neira, Wilberto ^a   Taimi, Mohammed ^a   Kohlhagen, Glenda ^a   Shimizu, Tsunehiro ^a   Losiewicz, Michael D ^a   Pommier, Yves ^a   Sausville, Edward A ^a   Senderowicz, Adrian M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME INHIBITION; GROWTH INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0031963058     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.458     Document Type: Article

References (43)

1. Kaur G, Stetler-Stevenson M, Sehers S, Worland R, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736, 1992
2. Czech J, Hoffmann D, Naik R, Sedlacek H-H: Antitumoral activity of flavone L86-8275. Int J Oncol 6:31, 1995
3. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589, 1994
4. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase CDK2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973, 1996
5. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol 46:1831, 1993
6. De Azevedo WF Jr. Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93:2735, 1996
7. Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 10:587, 1996
8. Eastman A: Apoptosis: A product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 121:160, 1993
9. Solary E, Bertrand R, Pommier Y: Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemia HL60 cells. Leuk Lymphoma 15:21, 1994
10. Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR, Gewirtz DA: Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: Association with enhanced fragmentation of mature DNA. Cancer Res 52:6270, 1992
11. Dou QP, An B, Will PL: Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci USA 92:9019, 1995
12. Senderowicz AM, Headlee D, Stinson S, Lush RM. Tompkins A, Brawley O, Bergan R, Figg WD, Smith A, Sausville EA: Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. 9th National Cancer Institute-European Organization for Research on Treatment of Cancer Symposium Proceedings. Ann Oncol 7:77, 1996 (suppl 1)
13. Senderowicz AM, Kaur G, Sainz E, Laing C, Inman WD, Rodriguez J, Crews P, Malspeis L, Grever MR, Sausville EA, Duncan KL: Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst 87:46, 1995
14. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA: Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927, 1995
15. Bertrand R, Solary E, Jenkins J, Pommier Y: Apoptosis and its modulation in human promyelocytic HL-60 cells treated With DNA topoisomerase I and II inhibitors. Exp Cell Res 207:388, 1993
16. Leteurtre F, Kohlhagen G, Fesen MR, Tanizawa A, Konn KW, Pommier Y: Effects of DNA methylarion on topoisomerase I and II cleavage activities. J Biol Chem 269:7893, 1994
17. Markovits J, Larsen AK, Segal-Bendirdjian E, Fosse P, Saucier JM, Gazit A, Levitzki A, Umezawa K, Jacquemin-Sablon A: Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem Pharmacol 48:549, 1994
18. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT4 and HL-60 cells. Cancer Res 52:6200, 1992
19. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: Programmed cell death and the control of cell survival. Philos Trans R Soc Lond B Biol Sci 345:265, 1994
20. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
21. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976, 1993
22. Del Bino G, Li X, Traganos F, Darzynkiewicz Z: Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 8:281, 1996
23. Wyllie AH: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
24. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23, 1996
25. Hara S, Halicka HD, Bruno S, Gong J, Traganos F, Darzynkiewicz Z: Effect of protease inhibitors on early events of apoptosis. Exp Cell Res 223:372, 1996
26. Barry MA, Eastman A: Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys 300: 440, 1993
27. Barry MA, Eastman A: Endonuclease activation during apoptosis: The role of cytosolic Ca2+ and pH. Biochem Biophys Res Commun 186:782, 1992
28. Carroll AG, Voeller HJ, Sugars L, Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23:123, 1993
29. Magnelli L, Cinelli M, Chiarugi V: Phorbol esters attenuate the expression of p53 in cells treated with doxorubicin and protect TS-p53/K562 from apoptosis. Biochem Biophys Res Commun 215: 641, 1995
30. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB, Mercer WE: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668, 1995
31. Yamato K, Yamamoto M, Hiramo Y, Tsuchida N: A human temperature-sensitive p53 mutant p53 Val-138: modulation of the cell cycle, viability and expression of p53 responsive genes. Oncogene 11:1, 1995
32. Rus HG, Niculescu F, Shin ML: Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol 156:4892, 1996
33. Reynolds JE, Li J, Craig RW, Eastman A: BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Exp Cell Res 225:430, 1996
34. Jacobsen MD, Weil M, Raff MC: Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. J Cell Biol 133:1041, 1996
35. Shimizu T, O'Connor P, Kohn KW, Pommier Y: Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55:228, 1995
36. Meikrantz W, Schlegel R: Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 271:10205, 1996
37. Park DS, Farinelli SE, Greene LA: Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J Biol Chem 271:8161, 1996
38. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6:393, 1996
39. Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143, 1996
40. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML: Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 130:157, 1995
41. Horteland S, Bosca L: 6-Mercaptopurine decreases the bcl-2/bax ratio and induces apoptosis in activated splenic B lymphocytes. Mol Pharmacol 51:414, 1997
42. Schwartz GK, Farsi K, Danso D, Dhupar SK, Kelsen D, Spriggs D: The protein kinase C (PKC) inhibitors UCN-01 and flavopiridol significantly enhance the cytotoxic effect of chemotherapy by promoting apoptosis in gastric and breast cells. Proc Am Soc Clin Oncol 15:501, 1996
43. Bible K, Kaufmann S: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856, 1996